Nideolo (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 signaling pathway, which increases antioxidant and cytoprotective gene expression. This reduces oxidative stress and inflammation while modulating immune‑cell activity, particularly T‑lymphocytes, leading to its therapeutic effects in multiple sclerosis and psoriasis.

The specific dose of Nideolo is determined by the prescribing clinician based on the patient’s condition, disease severity, and individual response. Healthcare professionals follow local prescribing guidelines to set the appropriate dosage regimen.

The safety of dimethyl fumarate in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Nideolo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other oral disease‑modifying therapies, dimethyl fumarate offers a distinct mechanism via Nrf2 activation and has a favorable efficacy profile for reducing relapses. Its safety profile includes common flushing and gastrointestinal effects, whereas some alternatives may have different risk patterns such as cardiac or hepatic concerns.

Nideolo should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keeping the product in a dry, controlled environment helps maintain its stability and potency throughout its shelf life.

Nideolo is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and should not alter the regimen without medical advice.

The most serious risks include progressive multifocal leukoencephalopathy (PML), severe infections, and significant hepatic injury. Regular monitoring of lymphocyte counts and liver function tests is essential to detect early signs of these potentially life‑threatening complications.

Nideolo is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any excipients, and it should be avoided in individuals with active severe infections, severe hepatic impairment, or those receiving live attenuated vaccines. Clinicians must assess each patient’s medical history before initiating therapy.